Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
Novartis Pharmaceuticals
Alexa B Kimball; Gregor B E Jemec; Afsaneh Alavi; Ziad Reguiai; Alice B Gottlieb; Falk G Bechara; Carle Paul; Evangelos J Giamarellos Bourboulis; Axel P Villani; Andreas Schwinn; Franziska Ruëff; Larisha Pillay Ramaya; Adam Reich; Ines Lobo; Rodney Sinclair; Thierry Passeron; Antonio Martorell; Pedro Mendes-Bastos; Georgios Kokolakis; Pierre-Andre Becherel; Magdalena B Wozniak; Angela Llobet Martinez; Xiaoling Wei; Lorenz Uhlmann; Anna Passera; Deborah Keefe; Ruvie Martin; Clarice Field; Li Chen; Marc Vandemeulebroecke; Shoba Ravichandran; Elisa Muscianisi